LNZ101 (Aceclidine /Brimonidine) ophthalmic solution + LNZ100 (Aceclidine) ophthalmic solution + Placebo (Vehicle) ophthalmic solution
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Mar 4, 2024 → Apr 10, 2024
NCT ID
NCT06270030About LNZ101 (Aceclidine /Brimonidine) ophthalmic solution + LNZ100 (Aceclidine) ophthalmic solution + Placebo (Vehicle) ophthalmic solution
LNZ101 (Aceclidine /Brimonidine) ophthalmic solution + LNZ100 (Aceclidine) ophthalmic solution + Placebo (Vehicle) ophthalmic solution is a phase 1 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT06270030. Target conditions include Presbyopia.
What happened to similar drugs?
1 of 6 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (5)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06270030 | Phase 1 | Completed |
Competing Products
14 competing products in Presbyopia